NYSE:EWEdwards Lifesciences Stock Price, Forecast & News

Edwards Lifesciences' stock was trading at $65.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EW stock has increased by 5.2% and is now trading at $69.19. View which stocks have been most impacted by Coronavirus.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 7 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Edwards Lifesciences.

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Edwards Lifesciences.

Edwards Lifesciences Corp (NYSE:EW) released its quarterly earnings data on Thursday, April, 23rd. The medical research company reported $0.50 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.43 by $0.07. The medical research company earned $1.13 billion during the quarter, compared to analysts' expectations of $1.03 billion. Edwards Lifesciences had a net margin of 24.71% and a return on equity of 31.83%. The company's quarterly revenue was up 13.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.44 EPS. View Edwards Lifesciences' earnings history.

Edwards Lifesciences's stock split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were payable to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

Edwards Lifesciences issued an update on its FY20 earnings guidance on Thursday, April, 23rd. The company provided earnings per share (EPS) guidance of $4.75-5.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.46. The company issued revenue guidance of $4.00-4.50 billion, compared to the consensus revenue estimate of $4.08 billion.

23 Wall Street analysts have issued 1-year price targets for Edwards Lifesciences' shares. Their forecasts range from $51.67 to $100.00. On average, they expect Edwards Lifesciences' share price to reach $82.77 in the next year. This suggests a possible upside of 19.6% from the stock's current price. View analysts' price targets for Edwards Lifesciences.

Headlines about EW stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Edwards Lifesciences earned a news impact score of 1.6 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Edwards Lifesciences.

Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Steris (STE), Masimo (MASI) and Insulet (PODD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Walt Disney (DIS), Home Depot (HD), Visa (V), Adobe (ADBE), Mastercard (MA), QUALCOMM (QCOM) and CVS Health (CVS).

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences' stock is owned by a number of institutional and retail investors. Top institutional investors include M&R Capital Management Inc. (0.00%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View institutional ownership trends for Edwards Lifesciences.

EW stock was purchased by a variety of institutional investors in the last quarter, including M&R Capital Management Inc.. View insider buying and selling activity for Edwards Lifesciences.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EW stock can currently be purchased for approximately $69.19.

Edwards Lifesciences has a market capitalization of $42.87 billion and generates $4.35 billion in revenue each year. The medical research company earns $1.05 billion in net income (profit) each year or $1.86 on an earnings per share basis. Edwards Lifesciences employs 13,900 workers across the globe.

The official website for Edwards Lifesciences is www.edwards.com.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]